Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Other

Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

Medicenna Therapeutics

By The Northwire Desk — AI Analysis Apr 14, 2026 · 07:30 MDNA · 0.615 MEDICENNA THERAPEUTICS CORP. J
Executive Summary
  • The most recent release (April 14, 2026) announces a presentation at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026.
  • Content includes a corporate update and MDNA113 preclinical data from the AACR Annual Meeting.
  • This follows the March 18, 2026 announcement regarding the same AACR presentation of updated pre-clinical data for MDNA113.
  • The February 13, 2026 quarterly results showed cash of $10.6 million with a runway into Q3 2026 and clinical updates on MDNA11 (ORR 36-43%) and Bizaxofusp (OS doubling in GBM).
  • Historical data from November 2025 indicated a higher cash balance ($15.7 million) and the initiation of the NEO-CYT trial collaboration with Fondazione Melanoma Onlus.
Material Impact
  • The April 14 announcement is confirmatory rather than transformative, reiterating an already disclosed presentation schedule (AACR data).
  • No new clinical efficacy data or financial milestones are introduced in this specific release; it serves as standard investor relations visibility.
  • Given the stock's significant decline from $1.64 to $0.65 despite positive clinical news in February and March, the market appears to be pricing in capital dilution risks rather than clinical success alone.
  • The materiality is neutral because the information was largely anticipated by the previous month's release cycle and does not alter the fundamental cash runway timeline or clinical trajectory.
MDNA · Price
Company Overview
  • Company: Medicenna Therapeutics is a clinical-stage biopharmaceutical company focused on oncology immunotherapies.
  • Flagship Project: MDNA11, a long-acting IL-2 Superkine designed to activate CD8+ T cells while sparing regulatory T cells.
  • Pipeline Assets:
    • MDNA113: First-in-class tumor-anchored anti-PD-1 x IL-2 bifunctional superkine (Preclinical/IND stage).
    • Bizaxofusp (MDNA55): IL-4 Empowered Superkine for recurrent glioblastoma (Phase 2b completed, seeking partnership).
  • Development Status: MDNA11 is in Phase 1/2 ABILITY-1 trial; Bizaxofusp has shown median OS of 13.6 months vs 7 months standard care in Phase 2b.
Read the original news release →

More from MEDICENNA THERAPEUTICS CORP. J

Jun 26, 2026 · 08:45

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Earnings Jun 11, 2026 · 07:00

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

M&A / Property Jun 03, 2026 · 07:00

ASCO Presentation Offers No New Catalysts as Dilutive Capital Raise Extends Runway Amid Steep Equity Erosion

Other May 28, 2026 · 09:10

Medicenna Secures $12.4M Lifeline Amidst Dilution Concerns and Clinical Milestones

Financings May 22, 2026 · 07:00

Medicenna Files $13M Financing at Deep Discount as Cash Dwindles and Stock Spirals

Financings May 19, 2026 · 07:00

Financing Finalized at Discount as Dilution Concerns Weigh on Stock

Financings